Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2023 0 · FY2024 90 — 2-yr total 90
Abulpharm LLC is a Tbilisi-based pharmaceutical distributor and wholesaler set up with Turkish investment (~USD 2m), operating a pharmaceutical warehouse in the Gldani industrial zone with regional export activity, particularly to Russia.
| Line item | 2023 | 2024 | CAGR |
|---|---|---|---|
| Total Revenue | 134,251 | 341,277 | +154.2% |
| Total COGS | 84,015 | 161,618 | +92.4% |
| Gross Profit | 50,236 | 179,659 | +257.6% |
| Gross Margin | 37.4% | 52.6% | |
| Other Operating Income | 0 | 7,128 | |
| 1,855 | 6,841 | +268.8% | |
| EBITDA | 48,381 | 179,946 | +271.9% |
| EBITDA Margin | 36.0% | 52.7% | |
| Total D&A | 0 | 0 | |
| EBIT / Operating Income | 48,381 | 179,946 | +271.9% |
| Profit Before Tax | 48,381 | 179,946 | +271.9% |
| Total Income Tax | 0 | 0 | |
| Net Profit / (Loss) | 48,381 | 179,946 | +271.9% |
| Net Margin | 36.0% | 52.7% | |
| Other Comprehensive Income | 1,225 | 7,858 | +541.5% |
| Total Comprehensive Income | 49,606 | 187,804 | +278.6% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →